Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

CLINUVEL Files NEURACTHEL Dossier With European Regulators

CUV: $7.22 -1.50% · MC: $375M

CLINUVEL has filed for marketing authorisation of NEURACTHEL Instant in three European Union countries, beginning regulatory review of its second pharmaceutical product. Approval could allow launches in up to three initial markets; the review is intended to take 300 days, excluding possible pauses, and the product is not yet approved anywhere.

Source announcements: 2026-10-30 08:30 to 2026-10-30 08:30 Sydney time
Story updated 2026-10-30 08:36 Sydney time
SourcesCLINUVEL files NEURACTHEL Instant dossier
Comments